Skip to main content
Premium Trial:

Request an Annual Quote

Syrrx, Genomics Institute to Co-Develop Structural Proteomics Tools

NEW YORK, Jan 4 – Structural proteomics company Syrrx said Thursday it has entered into a five-year strategic alliance with the Genomics Institute of the Novartis Research Foundation (GNF).

Under the terms of the agreement, GNF has granted Syrrx an exclusive license to tools it has developed for cloning, protein expression, protein purification, and protein crystallization. Syrxx will also have access to GNF’s collection of X-ray diffraction data for use within the field of structural proteomics.

In exchange, GNF will take a minority equity position in Syrrx and a seat on the company’s board of directors.

Under the collaboration, Syrrx and GNF will co-develop automated systems to streamline the protein structure determination process. The first technologies they expect to develop include high-throughput fermentation technology, high-throughput protein purification robotics, and a high-throughput protein crystallization system.

Further terms of the alliance were not disclosed.

Syrrx plans to use the developed technologies to identify protein variants suitable for crystallization.

" This collaboration will enable our two organizations to combine our knowledge of biochemistry, computational biology, and engineering to reach goals efficiently," Wendell Wierenga, Syrrx's CEO, said in a statement.  

GNF uses functional genomics and advanced technologies to enable biological discovery. The Novartis Research Institute has committed $250 million in funding to the Genomics Institute and is currently building a 180,000 square foot laboratory complex in La Jolla, Calif.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.